Precision BioSciences has moved quickly to partner its CAR-T cell therapy candidate. Less than three weeks after confirming it planned to partner the program, the biotech has agreed to offload the asset to Imugene for $21 million upfront and much more on the back end.

Precision BioSciences已迅速与其CAR-T细胞治疗候选人合作。在确认计划与该计划合作后不到三周，生物技术公司已同意将资产退还给Imugene，前期为2100万美元，后端为更多。

North Carolina-based Precision shared early-phase clinical trial data on the allogeneic CAR-T candidate, the CD19-directed azercabtagene zapreleucel (azer-cel), in May. The clinical trial linked azer-cel to a 41% complete response in relapsed or refractory non-Hodgkin lymphoma patients. Precision saw the highest complete response rate, 61%, in a subset of 18 CD19-positive, CAR-T relapsed patients..

基于北卡罗来纳州Precision的Precision在5月共享同种异体CAR-T候选者CD19指导的azercabtagene zapreleucel（azer-cel）的早期临床试验数据。临床试验将azer-cel与41%复发或难治性非霍奇金淋巴瘤患者。在18例CD19阳性，CAR-T复发患者中，Precision的完全缓解率最高，为61%。。

Subsequent talks with the FDA provided clarity on a “potential pathway toward registration,” but, with multiple programs on the go, Precision opted against walking the path itself, choosing instead to look for a partner. Enter Imugene.

随后与FDA的会谈为“注册的潜在途径”提供了清晰的信息，但是，在多个计划中，Precision选择不走这条道路，而是选择寻找合作伙伴。输入Imugene。

The Australian biotech has agreed to pay $21 million upfront in cash and equity for global rights to the CAR-T candidate. Imugene will hand over another $8 million, again in cash and equity, once the therapy completes phase 1b dosing in the CAR-T relapsed large B-cell lymphoma patient population. As the asset advances, Precision could receive up to $198 million in milestones plus double-digit royalties on net sales..

澳大利亚生物技术公司已同意为CAR-T候选人支付全球权利现金和股权2100万美元。一旦治疗完成CAR-T复发的大B细胞淋巴瘤患者群体的1b期给药，Imugene将再次移交800万美元，现金和股权。随着资产的进步，Precision可以获得高达1.98亿美元的里程碑以及净销售额的两位数版税。。

Imugene has also secured an option to develop up to three other cancer programs. Each of the programs is tied to $145 million in milestones. Precision’s phase 1 PBCAR19B stealth cell and multiple myeloma CAR-T assets, plus rights to azer-cel in non-oncology indications, remain available for partnering..

Imugene还可以选择开发多达三个其他癌症项目。每个项目的里程碑都与1.45亿美元相关。Precision的第1阶段PBCAR19B隐形细胞和多发性骨髓瘤CAR-T资产，以及非肿瘤学适应症中azer-cel的权利，仍可供合作。。

Precision wants to partner the cell therapy programs and pivot to the in vivo gene editing applications of its technology. The Imugene deal supports the plan by adding to Precision’s bank balance and wiping $20 million off its annual spending, changes that could extend the biotech’s cash runway to the third quarter of 2025, up from the first quarter of 2025 under the previous plan..

Precision希望与细胞治疗计划合作，并转向其技术的体内基因编辑应用。Imugene协议通过增加Precision的银行余额并从其年度支出中吸取2000万美元来支持该计划，这些变化可能会将生物技术的现金跑道延长至2025年第三季度，而不是之前计划下的2025年第一季度。。

Over the length of its cash runway, Precision plans to advance a chronic hepatitis B gene editing program, which it plans to file to test in humans next year, and support other in vivo gene editing programs it is working on with Eli Lilly and Novartis.

在其cash跑道的整个过程中，Precision计划推进一项慢性乙型肝炎基因编辑计划，该计划将于明年提交人体测试，并支持其与礼来公司合作的其他体内基因编辑计划。诺华。

It appears investors may still need some convincing. While Precision’s share price did rise 30% in early premarket trading Wednesday in the wake of news of the Imugene deal, the stock still only sits at 69 cents.

看起来投资者可能仍然需要一些说服力。虽然根据Imugene交易的消息，Precision的股票价格在周三早期上市前交易中确实上涨了30%，但该股票仍然只有69美分。